MindBio Therapeutics Corp. (MBIO.CN)
| Previous Close | 0.0450 |
| Open | 0.0450 |
| Bid | 0.0450 x N/A |
| Ask | 0.0500 x N/A |
| Day's Range | 0.0400 - 0.0500 |
| 52 Week Range | 0.0150 - 0.0900 |
| Volume | |
| Avg. Volume | 47,065 |
| Market Cap | 6.652M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ACCESSWIREMindBio Therapeutics Reports Secondary Data: Improvement of Psychological Outcomes & Safety Results in Depressed Patients from Phase 2A Depression Trial
VANCOUVER, BC / ACCESSWIRE / June 12, 2024 /MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), a leading biopharmaceutical company in psychiatric medicine development using microdoses of psychedelic medicines, is delighted ...
- ACCESSWIRE
Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders
MindBio to develop the novel psilocin prodrug for neuropsychiatric indications utilizing microdosing to reduce or eliminate hallucinogenic impact of psychedelic compounds VANCOUVER, BC / ACCESSWIRE / May 14, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), ...
- ACCESSWIRE
MindBio Therapeutics Scientists Present Landmark Women’s Health Trials. Company To Release Phase 2A Depression Trial Secondary Data This Month
VANCOUVER, BC / ACCESSWIRE / May 2, 2024 /MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), a clinical stage biopharma company pioneering microdosing treatments for mental health conditions showcases Dr Rachael Sumner, ...
